Aethlon medical announces publication of preclinical data showing ability of the hemopurifier® to remove platelet-derived extracellular vesicles from plasma

Results reinforce the current australian oncology clinical trial and support investigation of the hemopurifier across multiple indications san diego , may 14, 2025 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the publication ( https://www.biorxiv.org/cgi/content/short/2025.05.09.652772v1 ) of a pre-clinical ex vivo study in pre-print vehicle biorxiv, entitled, "ex vivo removal of cd41 positive platelet microparticles from plasma by a medical device containing a galanthus nivalis agglutinin (gna) affinity resin." aethlon medical's hemopurifier® is a therapeutic blood filtration system designed to bind and remove harmful extracellular vesicles (evs or exosomes) and life-threatening viruses from blood and other biological fluids, properties that support its evaluation not only in oncology and infectious diseases, but also in the organ transplantation and other areas of significant unmet medical need.
AEMD Ratings Summary
AEMD Quant Ranking